This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Ebstein Anomaly에브스타인이상 (Ebstein이상)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q22.5 | Special Copayment Reduction: V146 (rare disease Special Copayment Reduction)
B. SynonymsEbstein anomaly, Ebstein malformation, tricuspid valve dysplasia
C. Adult onsetLikelihood of first presentation in adulthood moderate — in mild to moderate forms, patients may be asymptomatic or mildly symptomatic from school age to adulthood and first diagnosed because of paroxysmal tachycardia (WPW-related), a heart murmur or exercise intolerance. Cases in which Ebstein anomaly is confirmed by echocardiography after a WPW pattern is found on the electrocardiogram are not uncommon in adult cardiology clinics.
1. History1866: description by Ebstein → 1970s: association with lithium reported → 2007: Cone operation technique (da Silva) established → advances in WPW catheter ablation.
2. CausesAbnormal delamination of the septal and posterior leaflets of the tricuspid valve → apical displacement. Formation of an atrialized right ventricle. Lithium exposure: risk increased about 1.5–3-fold. MYH7, NKX2.5 variants.
3. GeneticsMostly sporadic. MYH7 variants (familial). Associated WPW syndrome in 15–30% (accessory pathways). CMA/FISH recommended. Fetal echocardiography mandatory with lithium use during pregnancy.
4. General epidemiology0.3–0.5% of congenital heart disease. Relatively high proportion diagnosed in adulthood. Diagnosed after presenting with paroxysmal tachycardia (WPW). Korea Q22.5, Special Copayment Reduction V146.
5. PathophysiologyAbnormal position of the tricuspid valve → regurgitation + atrialized right ventricle. Right-to-left shunt (ASD/PFO) → cyanosis. Accessory pathway → WPW → risk of paroxysmal tachycardia and sudden death.
6. SymptomsSevere neonatal: cyanosis, massive cardiomegaly, right heart failure. Mild to moderate: exercise intolerance, palpitations (WPW tachycardia), syncope, mild cyanosis.
7. SignsCyanosis, tricuspid regurgitation murmur, four heart sounds (sail sound). Electrocardiogram: WPW pattern, right atrial enlargement, RBBB. Echocardiography: apical displacement of the septal leaflet ≥ 8mm/m², atrialized right ventricle.
8. ScreeningSevere: prenatal fetal echocardiography, CCHD screening. Adults: echocardiography when WPW findings are seen on the electrocardiogram. Pregnant women taking lithium: detailed fetal echocardiography (20–22 weeks).
9. DiagnosisEchocardiography (septal leaflet displacement distance, Celermajer classification, regurgitation severity). Cardiac MRI (right ventricular volume and function). EPS (accessory pathway location). Electrocardiogram/Holter.
10. TreatmentCone operation (tricuspid valve reconstruction) for moderate or worse symptoms. WPW: catheter ablation (RFCA). Concurrent ASD closure. Severe neonates: PGE1, BT shunt. Medications: treatment of heart failure and arrhythmias.
11. PrognosisCone operation mortality 1–3%, 10-year reoperation 10–15%. Risk of sudden death with WPW (multiple or short-refractory-period accessory pathways). Pregnancy: possible in moderate cases, but multidisciplinary counseling is essential.
12. PreventionPregnant women taking lithium: fetal echocardiography (20–22 weeks). Prenatal diagnosis and CCHD screening. After diagnosis, ACHD follow-up and early evaluation and ablation of WPW (prevention of sudden death).
13. ReferencesList of 10 key references

1. History

Ebstein anomaly is a congenital heart disease in which the tricuspid valve is displaced downward toward the apex from its normal position and attached there; it was first described in 1866 by the German physician Wilhelm Ebstein (1836–1912). Ebstein discovered this unique tricuspid malformation at autopsy and described in detail the structure in which the septal leaflet and posterior leaflet of the tricuspid valve descend toward the apex so that part of the right ventricle is functionally atrialized.

Clinical interest grew from the mid-20th century, when advances in cardiac catheterization and echocardiography made diagnosis possible in living patients. In the 1950s, cardiac catheterization elucidated the abnormal hemodynamics in the atrialized right ventricle.

The first surgical treatment was attempted in 1958 but outcomes were poor, and various tricuspid valvuloplasty and replacement techniques were developed in the 1970s–80s. In 2007, the American cardiac surgeon Joseph Dearani and colleagues developed and published the Cone operation technique. The Cone operation detaches all three leaflets of the tricuspid valve and reattaches them above the tricuspid annulus; its results in correcting tricuspid regurgitation are superior to previous techniques, and it has now become the standard surgical technique preferred at many specialized centers.

Ebstein anomaly has also attracted attention for its association with lithium. There were early reports (1970s) that lithium exposure in early pregnancy increases the risk of Ebstein anomaly, but subsequent studies confirmed that the increase in risk is lower than initially reported. However, because there is evidence of a slightly increased risk of fetal heart malformations (especially Ebstein anomaly) with lithium use in early pregnancy, this is considered when deciding on mood stabilizer use during pregnancy.


2. Causes

The cause of Ebstein anomaly lies in an abnormality of the delamination process of the septal and posterior leaflets of the tricuspid valve during embryonic development. In normal development, the tricuspid leaflets separate (delaminate) from the ventricular myocardial layer and move to the position of the atrioventricular annulus (AV annulus), but in Ebstein anomaly this delamination is incomplete, so the septal and posterior leaflets remain attached at a low position toward the apex.

As a result, part of the tricuspid valve (the anterior leaflet is mostly attached in its normal position but is large and sail-like (sail-like leaflet)) lies below the functional tricuspid annulus, and the right ventricular myocardium in this region becomes thin and functionally atrialized (atrialization). The larger the atrialized right ventricle (atrialized RV) portion, the smaller the functional right ventricle and the more severe the tricuspid regurgitation.

Genetic causes associated with Ebstein anomaly include reported MYH7 (sarcomeric protein myosin heavy chain) variants, which are found in familial Ebstein anomaly. There are also cases in which variants in cardiac transcription factor genes such as NKX2.5, GATA4 and GATA6 are associated with Ebstein anomaly. Most Ebstein anomaly is sporadic, and the familial recurrence rate is low.

The best-known environmental cause is lithium exposure in early pregnancy. Inhibition of the inositol-phosphatide signaling pathway has been proposed as the mechanism of lithium's embryonic cardiac toxicity. With lithium exposure, the risk of Ebstein anomaly is currently estimated to increase about 1.5–3-fold over baseline risk, and the absolute risk remains low. As for other environmental factors, some studies have reported that benzodiazepine exposure in early pregnancy may be associated, but the evidence is insufficient.


3. Genetics

The genetics of Ebstein anomaly are characterized by mostly sporadic occurrence. Familial recurrence has been reported, but the familial recurrence rate is estimated to be low. Cases in which a specific single-gene cause has been established are rare.

MYH7 (sarcomeric protein myosin heavy chain β, 14q12) variants are the best-known gene associated with familial occurrence of Ebstein anomaly. MYH7 encodes a protein central to the mechanism of myocardial contraction and, in addition to Ebstein anomaly, is associated with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Cases of HCM occurring in families of patients with Ebstein anomaly have also been reported.

22q11.2 deletion is rarely reported in Ebstein anomaly. Rare cases of NKX2.5, GATA4 and GATA6 variants associated with Ebstein anomaly have also been reported. The association between Ebstein anomaly and Wolff-Parkinson-White (WPW) syndrome is also important. In about 15–30% of patients with Ebstein anomaly, an accessory pathway is present and WPW syndrome may occur, which is associated with paroxysmal tachycardia and the risk of sudden death. Electrocardiography and electrophysiologic studies to evaluate for an accessory pathway are important in all patients with Ebstein anomaly.


4. General epidemiology

Ebstein anomaly is a rare malformation accounting for about 0.3–0.5% of all congenital heart disease, occurring at a frequency of about 1 in 10,000–20,000 live births. Some studies also report a lower frequency of 1/200,000. The clinical spectrum of Ebstein anomaly is very wide, ranging from severe forms presenting with serious cyanosis in the neonatal period to mild forms discovered incidentally by a heart murmur in adulthood.

In Korea it is classified under code Q22.5 and is eligible for Special Copayment Reduction V146. Among congenital heart diseases, Ebstein anomaly is relatively often first diagnosed in adulthood and is one of the main diagnoses in ACHD clinics. Patients with mild forms of Ebstein anomaly may show a heart murmur or mild symptoms in childhood and then be confirmed by detailed echocardiography in adulthood.

Because of the association between Ebstein anomaly and WPW syndrome, Ebstein anomaly is sometimes discovered in patients presenting to a cardiology clinic with a chief complaint of paroxysmal tachycardia. Because of the epidemiological association with lithium exposure during pregnancy, fetal cardiac screening is recommended when counseling women taking lithium prescribed by psychiatry about pregnancy.


5. Pathophysiology

The core pathophysiology of Ebstein anomaly is tricuspid regurgitation and reduced right ventricular function due to the abnormal position of the tricuspid valve. As the septal and posterior leaflets of the tricuspid valve descend toward the apex, the functional tricuspid annulus narrows and the valve shape is distorted, causing regurgitation.

Atrialized right ventricle: the portion of the right ventricle above the tricuspid attachment, i.e., between the normal tricuspid annulus and the actual valve attachment, functionally dilates and contracts together with the right atrium, so the size of the actually functioning right ventricle becomes smaller. The wall of this atrialized right ventricle becomes thin and moves passively, further reducing the effective contractile volume of the right ventricle.

Tricuspid regurgitation → right atrial dilation → atrial-level right-to-left shunt (when a PFO or ASD is present) → cyanosis. Severe regurgitation and reduced right ventricular function → right heart failure (hepatomegaly, leg edema). Accessory pathway: in Ebstein anomaly, accessory pathways are commonly present (15–30%) in association with abnormal development of the atrioventricular annulus, and Kent bundles exist on the right side, single or multiple. This forms the basis of WPW-related paroxysmal tachycardia and sudden death.


6. Symptoms

The symptoms of Ebstein anomaly vary greatly according to the severity of the malformation, from neonatal cyanosis to an asymptomatic state in adulthood.

Severe neonatal Ebstein anomaly: tricuspid regurgitation is very severe and pulmonary blood flow is reduced, so serious cyanosis, cardiomegaly (massive cardiomegaly with the heart occupying most of the chest, cardiomegaly with "wall-to-wall heart"), hypoxemia and right heart failure appear in the neonatal period. The prognosis of this form is very poor.

Mild to moderate Ebstein anomaly (childhood to adulthood): exertional dyspnea and fatigue, palpitations (paroxysmal supraventricular tachycardia, WPW-related), syncope and mild cyanosis (decreased oxygen saturation from right-to-left shunting during exercise when an ASD or PFO is present) appear. In mild forms, symptoms may be absent or mild until adulthood, and it may be discovered incidentally by a heart murmur.

WPW-related symptoms: when an accessory pathway is present in Ebstein anomaly, paroxysmal increases in heart rate (palpitations), precordial discomfort, dizziness and syncope may occur. When tricuspid regurgitation worsens, symptoms of right heart failure (abdominal distension, leg edema, fatigue) appear.


7. Signs

On physical examination, cyanosis (moderate to severe, when ASD/PFO is present), clubbing, leg edema and jugular venous distension (in right heart failure) are observed. A holosystolic murmur due to tricuspid regurgitation is heard at the left lower sternal border and the apex. A split first heart sound (split S1) or additional heart sounds (four heart sounds: sail sound) are characteristic auscultatory findings of Ebstein anomaly. Hepatomegaly, ascites (in severe right heart failure).

Electrocardiogram: WPW pattern (delta wave, short PR, widened QRS) observed in about 15–30%. Enlarged P waves (right atrial enlargement: peaked P in V1). Incomplete or complete right bundle branch block (RBBB). Chest X-ray: cardiomegaly (especially right-sided), widened cardiac base ("box-shaped heart"). Decreased pulmonary vascular markings. Echocardiography: apical displacement distance of the septal tricuspid leaflet (apical displacement ≥ 8 mm/m² is the diagnostic criterion), sail-like shape of the anterior leaflet, size of the atrialized right ventricle, degree of tricuspid regurgitation, right ventricular function.


8. Screening

Screening for Ebstein anomaly is done through prenatal fetal echocardiography and neonatal CCHD oxygen saturation screening. Severe forms are detected on prenatal fetal echocardiography by tricuspid regurgitation, right atrial and right ventricular dilation, and cardiomegaly. When decreased SpO2 is found on neonatal CCHD screening, the diagnosis is immediately confirmed by echocardiography.

Screening in adulthood: echocardiography to rule out Ebstein anomaly is performed in patients with paroxysmal tachycardia (palpitations) or a WPW pattern found on the electrocardiogram. In women who took lithium in early pregnancy, detailed fetal echocardiography at 20–22 weeks of gestation together with evaluation by a fetal cardiology specialist is recommended.


9. Diagnosis

Echocardiography is central to the diagnosis and severity assessment of Ebstein anomaly. Apical displacement distance of the septal tricuspid leaflet (apical displacement, mm/m²): ≥ 8 mm/m² is the diagnostic criterion. The size of the atrialized right ventricle, anterior leaflet shape (sail-like), severity of tricuspid regurgitation, right ventricular function, right atrial size, presence of ASD/PFO and direction of atrial-level shunting are assessed.

Cardiac MRI: useful for quantifying the volume and function of the right ventricle and atrialized right ventricle and for measuring the tricuspid regurgitant fraction. Electrocardiogram and Holter: assessment of WPW pattern, paroxysmal supraventricular tachycardia and atrial fibrillation. Electrophysiologic study (EPS): assessment of the location, number and conduction properties of accessory pathways; essential for planning catheter ablation.

Cardiac catheterization: when confirming the location of accessory pathways (including EPS) or measuring pulmonary artery pressure and pulmonary vascular resistance is needed. Celermajer classification (1:2:4:10 ratio system): severity is classified into 4 grades by the area ratio of atrialized right ventricle/(right ventricle + left ventricle) and used for prognostic prediction.


10. Treatment

Treatment of Ebstein anomaly varies with severity and age. Severe neonates: PGE1 (to maintain duct-dependent pulmonary blood flow), inhaled oxygen, mechanical ventilation. In some, a BT shunt or preparation for the Fontan pathway. Depending on severity, early surgery or palliative surgery in some.

Surgical tricuspid valvuloplasty or replacement: indications for surgery are moderate or worse tricuspid regurgitation + symptoms (exercise intolerance, cyanosis, heart failure), reduced right ventricular function, progressive dilation of the right atrium and right ventricle, and paroxysmal tachycardia with an accessory pathway. The Cone operation is currently the most preferred tricuspid valvuloplasty technique: all three leaflets of the tricuspid valve are fully detached from the tricuspid annulus, rotated clockwise to reconstruct a cone-shaped tricuspid valve, and then resutured at the normal tricuspid annulus position. An associated ASD is closed, and plasty of the anterior wall of the atrialized right ventricle (right ventricle exclusion or plication) is performed at the same time.

Treatment of accessory pathways (WPW): radiofrequency catheter ablation (RFCA) is the first-line treatment for symptomatic WPW. In Ebstein anomaly, right lateral or posterior accessory pathways are common and may be multiple, so the ablation success rate may be lower than in ordinary WPW. There is also a method of dividing the accessory pathway during surgery (surgical ablation). Medications: diuretics, ACE inhibitors and beta-blockers in accordance with heart failure management. Antiarrhythmic drugs: amiodarone, sotalol.


11. Prognosis

The prognosis of Ebstein anomaly varies greatly because of its wide spectrum of severity. Early mortality is high in the severe neonatal form, but in mild to moderate forms a relatively favorable prognosis into adulthood is possible with appropriate follow-up and selective surgery.

Short-term mortality after the Cone operation is reported to be about 1–3%. The 10-year reoperation rate is about 10–15%. Recurrence and progression of tricuspid regurgitation after the Cone operation are the main factors determining long-term prognosis. When right ventricular function is sufficiently preserved, quality of life and exercise capacity improve greatly after surgery.

Risk of sudden death with WPW syndrome: patients with Ebstein anomaly have a risk of sudden death from WPW-related ventricular fibrillation. The risk is particularly high when the refractory period of the accessory pathway is short or the pathways are multiple. Early catheter ablation of symptomatic WPW is important for preventing sudden death. Pregnancy: pregnancy is generally possible in moderate Ebstein anomaly, but because of the risks of worsening tricuspid regurgitation, arrhythmia and heart failure, multidisciplinary prenatal counseling is needed.


12. Prevention

No method of preventing the occurrence of Ebstein anomaly has currently been established. Because the risk of fetal Ebstein anomaly increases slightly in early pregnancy in pregnant women taking lithium, preconception counseling with a psychiatrist on the pregnancy risk-benefit of mood stabilizers is provided, and when lithium use during pregnancy is unavoidable, detailed fetal echocardiography at 20–22 weeks of gestation (by a fetal cardiology specialist) is recommended.

Prenatal fetal echocardiography (early diagnosis of severe Ebstein anomaly) and neonatal CCHD screening allow early detection and preparation for treatment. After diagnosis, regular follow-up at a specialized ACHD center (echocardiography, electrocardiogram, Holter, cardiopulmonary exercise testing) optimizes the timing of surgery, and WPW-related arrhythmias are evaluated and treated early to prevent sudden death. Patients after the Cone operation are followed regularly for surgical results and recurrence of tricuspid regurgitation.


13. References

  1. Ebstein W. Ueber einen sehr seltenen Fall von Insufficienz der Valvula tricuspidalis, bedingt durch eine angeborene hochgradige Missbildung derselben. Arch Anat Physiol. 1866;33:238-254.

  2. Celermajer DS, Bull C, Till JA, et al. Ebstein's anomaly: presentation and outcome from fetus to adult. J Am Coll Cardiol. 1994;23(1):170-176. DOI: 10.1016/0735-1097(94)90516-9. PMID: 8277471.

  3. Dearani JA, Danielson GK. Congenital Heart Surgery Nomenclature and Database Project: Ebstein's anomaly and tricuspid valve disease. Ann Thorac Surg. 2000;69(4 Suppl):S106-S117. DOI: 10.1016/S0003-4975(99)01268-2. PMID: 10798440.

  4. da Silva JP, Baumgratz JF, da Fonseca L, et al. The cone reconstruction of the tricuspid valve in Ebstein's anomaly. J Thorac Cardiovasc Surg. 2007;133(1):215-223. DOI: 10.1016/j.jtcvs.2006.09.018. PMID: 17198814.

  5. Correa-Villaseñor A, Ferencz C, Neill CA, Wilson PD, Boughman JA. Ebstein's malformation of the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study Group. Teratology. 1994;50(2):137-147. DOI: 10.1002/tera.1420500206. PMID: 7801315.

  6. Nora JJ, Nora AH, Toews WH. Lithium, Ebstein's anomaly, and other congenital heart defects. Lancet. 1974;2(7880):594-595. DOI: 10.1016/S0140-6736(74)91908-7. PMID: 4141119.

  7. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.

  8. Attenhofer Jost CH, Connolly HM, Dearani JA, Edwards WD, Danielson GK. Ebstein's anomaly. Circulation. 2007;115(2):277-285. DOI: 10.1161/CIRCULATIONAHA.106.619338. PMID: 17228014.

  9. Khositseth A, Danielson GK, Dearani JA, Munger TM, Porter CJ. Supraventricular tachyarrhythmias in Ebstein anomaly: management and outcome. J Thorac Cardiovasc Surg. 2004;128(6):826-833. DOI: 10.1016/j.jtcvs.2004.07.047. PMID: 15573064.

  10. Qureshi MY, O'Leary PW, Connolly HM. Cardiac imaging in Ebstein anomaly. Trends Cardiovasc Med. 2018;28(6):403-409. DOI: 10.1016/j.tcm.2018.02.001. PMID: 29452967.